Tuesday, August 25, 2026
← Back to archivePolicy
Policy•Fierce Biotech•Aug 24, 2026
Spruce’s successful FDA talks plant seeds for Q4 filing of ultra-rare disease drug
background ▾
- •FDA has cleared Spruce's drug substance and product analytical comparability strategies and submission structure, removing major regulatory uncertainty and enabling Q4 2026 filing for first-in-class MPS IIIB therapy
- •Manufacturing had been a critical risk factor delaying filing by nine months; Spruce's transfer to a global biologics manufacturer and aligned FDA feedback substantially de-risks this component
- •Peak sales projections exceed $300M with 2038 IP exclusivity; monitor Q4 2026 filing status, manufacturing scale-up execution for second supplier and larger bioreactor capacity, and potential approval timeline
Spruce BiosciencesBioMarinAllievextralesinidase alfaTA-ERT
→ Read original articlePolicy•Fierce Biotech•Aug 24, 2026
Roche, Eli Lilly net FDA approval for first-of-its-kind Alzheimer’s biomarker blood test
background ▾
- •First FDA-cleared blood test with dual rule-in and rule-out capability for Alzheimer's amyloid pathology, using a single biomarker (pTau217), addressing decades of clinical diagnostic challenges
- •Offers significant advantages over existing diagnostic methods (PET imaging, CSF biomarkers) by being non-invasive, cost-effective, and deployable across primary care and specialty settings
- •Watch for: Real-world clinical adoption rates, payer coverage and reimbursement decisions, integration into diagnostic guidelines, and competitive positioning against other emerging blood biomarker tests
RocheEli LillyElecsys pTau217
→ Read original articlePolicy•Fierce Biotech•Aug 25, 2026
Capricor secures reprieve as FDA extends DMD cell therapy review
background ▾
- •FDA granted 3-month extension (to Nov 22) to assess new data after Capricor pivoted from cardiomyopathy to upper limb function endpoint following negative advisory committee vote
- •The phase 3 trial failed to show statistically significant or clinically meaningful effect on the pre-specified upper limb endpoint; FDA's July briefing identified concerns about trial interpretation and evidence quality
- •Watch the November 22 PDUFA decision and whether the additional follow-up data and endpoint shift will overcome FDA's documented efficacy concerns—market skepticism suggests approval remains unlikely
Capricor Therapeuticsderamiocel
→ Read original articlePolicy•Endpoints News•Aug 24, 2026
FDA delays Capricor's deramiocel PDUFA date to review new data
background ▾
- •FDA PDUFA date extension indicates deramiocel faced approval challenges requiring substantial additional review
- •Company is pivoting to a more niche indication, suggesting acknowledgment that broader DMD claim may be insufficient for approval
- •Deramiocel's regulatory pathway remains uncertain; additional delays increase risk profile for the program
Capricor Therapeuticsderamiocel
→ Read original articlePolicy•STAT News•Aug 25, 2026
Opinion: Whale songs: the sounds of love and loss as heard by an OB-GYN
background ▾
- •This is an opinion/lifestyle piece with no relevance to pharmaceutical industry analysis, clinical development, or healthcare policy
Market Access
Market Access•Fierce Biotech•Aug 24, 2026
Roche pens $2.5B pact for Hanmi’s clinical-stage obesity drug targeting less-explored mechanism
background ▾
- •Roche is investing significantly in a first-in-class mechanism (UCN2 agonism) explicitly designed to preserve muscle mass during weight loss—addressing a major limitation of current GLP-1 therapies and reflecting evolving market expectations beyond simple weight reduction.
- •The $2.5B deal size reflects Roche's aggressive obesity strategy and willingness to pay for differentiated science; HM17321 is still in phase 1, making this a bet on mechanism and unproven efficacy in humans.
- •Watch for phase 2 trial data on weight loss, muscle preservation, and safety profile; competitive positioning versus emugrobart and other next-generation obesity therapies; and regulatory pathway clarity for a novel non-incretin mechanism.
RocheGenentechHanmi PharmaHM17321emugrobartenicepatide
→ Read original articleMarket Access•Fierce Biotech•Aug 25, 2026
Vacant lab space, shrinking workforce put Mass. in ‘unique position’ for biotech bounceback
background ▾
- •Massachusetts captured 25% of U.S. biotech VC funding in H1 2026 and produced 8 IPOs (62% of U.S. biopharma public listings), cementing its outsized influence on the national biotech sector
- •Early-stage funding is deteriorating: seed round amounts fell 40% to $4.6M average despite increased round count, signaling potential pipeline weakness in 5-10 years if trend continues
- •R&D workforce contracted 3,600 jobs (3.1%) in 2025—the first annual decline in 20+ years—though recent stabilization (Q4 gains) and optimism about capital redeployment may reverse the trend
MassBio
→ Read original articleMarket Access•Fierce Biotech•Aug 24, 2026
TME holds onto $1B dream for brain cancer drug as search for partners nears conclusion
background ▾
- •TME has narrowed its NOX-A12 partnership search to two final suitors and expects to announce a deal decision imminently—a critical milestone for a biotech with severely limited runway
- •The company is valuing NOX-A12 at $1 billion peak sales despite having only phase 1/2 data in combination with standard-of-care therapy for an indication with no curative options, suggesting aggressive commercial positioning
- •Watch for: (1) Identity of the selected partner and deal terms, (2) Phase 2 trial initiation timeline in the U.S. and Germany, and (3) whether TME can secure additional funding or partnerships for NOX-E36 to avoid cash depletion
TME PharmaRocheSingapore Eye Research InstituteNOX-A12olaptesed pegolNOX-E36
→ Read original articleMarket Access•Endpoints News•Aug 24, 2026
Option-to-acquire deals remain rare in biotech's buzzy M&A season
background ▾
- •Option-to-acquire structures remain an uncommon deal format despite recent visibility in the current M&A cycle
Clinical Trials
Clinical Trials•Fierce Biotech•Aug 24, 2026
Regenxbio gene therapy refiling plan derailed by FDA hold over spine MRI findings
background ▾
- •Clinical hold on RGX-121 blocks near-term resubmission despite investigator assessment that spine nodules/cystic masses are likely benign and asymptomatic, signaling FDA's heightened risk tolerance threshold for CNS gene therapies
- •The regulatory setback reflects episodic reversals in RGX-121's regulatory trajectory (rejected February → pathway cleared June → hold now) driven by emerging safety signals and enhanced surveillance revealing previously undetected findings
- •Key uncertainty: whether asymptomatic MRI findings represent a true safety signal unique to RGX-121's intracisternal/intraventricular dosing and AAV capsid, or reflect natural disease pathology in ultra-rare MPS II population with limited imaging history
RegenxbioNS PharmaRGX-121RGX-111RGX-202
→ Read original articleClinical Trials•Endpoints News•Aug 24, 2026
Bausch + Lomb plans Phase 3 trial for dry eye drop, despite missing mid-stage goal
background ▾
- •B+L's dry eye drop failed Phase 2 primary endpoint but company is proceeding to Phase 3, an unusual decision that warrants scrutiny of the underlying data
- •Lack of disclosed efficacy metrics and clinical rationale makes it difficult to assess whether Phase 3 advancement is justified or represents poor decision-making
- •Monitor Phase 3 design and enrollment strategy, and watch for peer-reviewed publication of Phase 2 results to understand the clinical case
Bausch + Lombdual-action dry eye drop (unnamed)
→ Read original articleClinical Trials•Endpoints News•Aug 24, 2026
News on AstraZeneca, Cytokinetics, Novartis — what to look out for at ESC 2026
background ▾
- •ESC 2026 will showcase competitive cardiovascular pipeline data from major players, indicating continued industry focus on heart disease indications
AstraZenecaIonicsCytokinetics
→ Read original article